Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04680156 · ClinicalTrials.gov registry record

Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

A clinical trial, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

Terminated
Registry status
120
Enrollment target

NCT04680156: Clinical Trial study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

NCT04680156 is a clinical trial that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04680156 was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

TERMINATED
Registry status
120 participants
Enrollment target

Study Summary

This is a long-term follow-up study to evaluate the safety and durability (efficacy) of response to EN3835 compared to placebo in participants who were treated in EN3835-210 or the pivotal Phase 3 parent studies for the treatment of AC of the shoulder (frozen shoulder).

Interventions

  • DRUG Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2020-12-17
Est. Completion 2022-09-12

What the Registry Record Tells You About NCT04680156

The ClinicalTrials.gov registry entry for NCT04680156 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies is the first listed.

NCT04680156 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04680156 about?

NCT04680156 is a clinical study titled "Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)". This is a long-term follow-up study to evaluate the safety and durability (efficacy) of response to EN3835 compared to placebo in participants who were treated in EN3835-210 or the pivotal Phase 3 parent studies for the treatment of AC of the shoulder (frozen shoulder).

What is the current status of trial NCT04680156?

This trial is currently terminated. The enrollment target is 120 participants. The study started on 2020-12-17. Estimated completion is 2022-09-12.

What interventions are being tested in trial NCT04680156?

The interventions under investigation include: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies (DRUG).

Who is sponsoring clinical trial NCT04680156?

This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.